Personalized medicine is an innovative concept that allows patients with a validated companion diagnosis (CoDx) to receive treatment using the most suitable drug. Currently, a major movement in the pharmaceutical industry involves the integrated use of multiple resources from external sources. To ascertain preferable interorganizational collaborations and their suitable exits, we compared the related transactions in personalized and nonpersonalized cancer drugs. We found that there were significantly more of some alliance deals in personalized medicine, and that market licenses, one of the exits, were well correlated with other alliances only in personalized medicine. Furthermore, four types of collaboration mode were identified, and more active collaborations with external partners were found to lead to more successful outcomes in personalized medicine development.

个性化医学是一个创新概念，可让伴有确诊诊断（CoDx）的患者接受使用最合适药物的治疗。当前，制药行业的一项重大运动涉及对来自外部资源的多种资源的综合利用。为了确定更好的组织间合作及其合适的退出渠道，我们比较了个性化和非个性化抗癌药物的相关交易。我们发现，个性化医学中的某些联盟交易显着增加，而市场许可证（存在的出口之一）仅与个性化医学中的其他联盟紧密相关。此外，还确定了四种类型的协作模式，